• This project is a multi-center, randomized controlled, intentionality analysis study.

⁃ Age ≥18 years old;

⁃ Histological or cytological examination confirmed clinically primary squamous non-small cell lung cancer stage IIIB-IV (according to AJCC 8th Edition);

⁃ Patients with stable moderate to severe chronic obstructive pulmonary disease (COPD) were diagnosed according to the GOLD2021 standard and the Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (Revised 2021), with blood eosinophils ≤300 /ul and ≥100 /ul;

⁃ The gene test showed that the driver gene (EGFR/ALK/BRAF/ROS1/KRAS/ HER2/MET/RET /NTRK) was negative;

⁃ ECOG PS 0-2 points;

⁃ Clinical evaluation is suitable for suglizumab combined with paclitaxel (albumin-bound) and carboplatin anti-tumor first-line therapy, as well as chronic obstructive pulmonary maintenance therapy with long-acting bronchodilators or inhaled corticosteroids;

⁃ Clinical records of suglizumab treatment, chemotherapy and other treatments are available;

⁃ Patients who have previously used bronchodilators and inhaled corticosteroids should undergo a washout period of at least 15 days;

⁃ Patients voluntarily join the project and sign informed consent;